Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an alzheimer's disease therapy
Ended Project Grant Awarded Last action
- Award ID
- R43AG078093
- Recipient
-
Bolden Therapeutics Inc. UEI PKW8T8LGCNH4
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $994,502
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Rhode Island, USA
Award details come from USAspending.gov.
Description
- Abstract
- There is an enormous need for therapeutics to prevent and treat alzheimer's disease (ad). Adult hippocampal neurogenesis (AHN) is critical for normal learning and memory, but IT declines in patients with ad. Work in animal models has underscored the role of AHN in improving cognition in the face of ad pathology. Thus, restoring AHN has emerged as an attractive target for an ad therapy. Augmenting AHN in the diseased brain is widely considered a potential therapeutic modality for the treatment of ad as well as for other disease states characterized by diminished neurogenesis e.g., frontotemporal dementia, treatment-resistant depression, post traumatic stress disorder, and stroke. However, drug development efforts to date have lacked sufficient specificity to selectively increase AHN without perturbing other stem cell regulatory mechanisms. In this phase I effort, bolden therapeutics will test exon-skipping antisense oligonucleotides (ASOS) against an undisclosed target expressed in neural stem cells to increase AHN. These candidate exon-skipping ASOS successfully skip the target region of interest in cultured cells and demonstrate favorable characteristics. We will use these ASOS in wild-type and ad mouse models to evaluate their effect on AHN, disease pathology, and cognition. Exon-skipping ASOS have emerged as effective and safe agents for regulating alternative splicing in the CNS. Determining in vivo efficacy of our candidate compounds is a critical step towards developing a highly targeted, safe and effective therapeutic for promoting AHN and improving cognition in ad. Following these studies, the exon-skipping ASOS will be ready for IND-enabling experiments and rapid preclinical development as we work towards developing a safe and effective therapy for ad and other disorders of impaired cognition via increasing AHN.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$598 | |
| Amendment | $0 | |
| Amendment | $497,550 | |
| Original award | $497,550 |
Quick answers
Who received award R43AG078093?
R43AG078093 was awarded to Bolden Therapeutics Inc. by National Institute on Aging (National Institutes of Health) on June 15, 2022.
How much is award R43AG078093 worth?
$994,502 has been obligated on R43AG078093.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award